{"filing":{"accession_number":"0001654954-26-007681","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"a8443q.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007681/a8443q.htm"},"events":[{"id":28089,"run_id":25673,"accession_number":"0001654954-26-007681","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This 6-K discloses positive Phase III trial results for Enhertu (trastuzumab deruxtecan) in first-line HER2-mutant lung cancer, showing statistically significant improvement in progression-free survival versus standard of care in the DESTINY-Lung04 trial. While this is a clinical milestone for an oncology product, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). The disclosure represents a material operational/clinical development milestone that would affect investor assessment of the company's pipeline and commercial prospects, particularly as Enhertu is already approved in multiple indications and this result supports potential label expansion to first-line treatment.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":29894,"accession_number":"0001654954-26-007681","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This 6-K discloses positive Phase III trial results for Enhertu (trastuzumab deruxtecan) in first-line HER2-mutant lung cancer, showing statistically significant improvement in progression-free survival versus standard of care in the DESTINY-Lung04 trial. While this is a clinical milestone for an oncology product, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). The disclosure represents a material operational/clinical development milestone that would affect investor assessment of the company's pipeline and commercial prospects, particularly as Enhertu is already approved in multiple indications and this result supports potential label expansion to first-line treatment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:57:08.389284+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-17"}]}